Key result
Ferric carboxymaltose assessed versus placebo for efficacy and safety in heart failure with iron deficiency.
Why the study?
Intravenous ferric carboxymaltose improves functional capacity and patient-reported outcomes in heart failure with reduced ejection fraction and iron deficiency, but morbidity and mortality data are limited.
Does intravenous ferric carboxymaltose improve a hierarchical composite of death, HF hospitalization, and 6-minute walk test distance in patients with HFrEF and iron deficiency?
RCT (n=3,014)
Double-blind
Randomized
Yes
Does intravenous ferric carboxymaltose improve a hierarchical composite of death, HF hospitalization, and 6-minute walk test distance in patients with HFrEF and iron deficiency?
The HEART-FID trial is designed to determine if long-term intravenous ferric carboxymaltose improves mortality, heart failure hospitalizations, and functional capacity in patients with HFrEF and iron deficiency.
No takes yet. Share an insight, caveat, or question.
Does not support routine ferric carboxymaltose use to reduce death or HF hospitalizations in HFrEF with ID; challenges extrapolation from prior symptom-focused trials to hard endpoints.
Mentz et al. (2021) conducted an RCT in Heart failure with reduced ejection fraction and iron deficiency (n=3,014). Ferric carboxymaltose vs. Placebo was evaluated on Hierarchical composite of death and HF hospitalization at 12 months and change from baseline to 6 months in the 6-minute walk test distance. The HEART-FID trial is a randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of ferric carboxymaltose in patients with heart failure and iron deficiency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: